• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WuXi PharmaTech goes private

WuXi PharmaTech goes private

August 17, 2015
CenterWatch Staff

WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and WuXi Merger, a wholly owned subsidiary of Parent.

Parent will acquire the company for cash consideration equal to $5.75 per ordinary share of the company and $46 per American Depositary Share (ADS) of the company, each representing eight shares, or about $3.3 billion in aggregate cash consideration. That figure represents a 16.5% premium over the closing price of $39.50 per ADS as quoted by the New York Stock Exchange on April 29, and a premium of 18.9% and 20.1%, respectively, over the company’s 30- and 60- trading day volume-weighted average price as quoted by the NYSE prior to April 29, 2015, the last trading day prior to the company’s announcement on April 30 that it had received a non-binding “going private” proposal.

Immediately following the consummation of the transactions contemplated by the merger agreement, Parent will be beneficially owned by a consortium comprised of:

  • New investors including affiliates of or funds managed or advised by Ally Bridge Group Capital Partners, Boyu Capital, Temasek Life Sciences Private and Ping An Insurance;
  • Hillhouse Fund II, an existing shareholder of the company and an affiliate of Hillhouse Capital; and
  • Founders and executive officers of the company who have elected to roll-over their interest in the company in connection with the merger including Dr. Ge Li, the chairman and chief executive officer; Xiaozhong Liu, an executive vice president and a director; Zhaohui Zhang, a senior vice president of operations, the head of domestic marketing and a director; and Dr. Ning Zhao, a senior vice president of operations, the head of corporate human resources and a director.

The merger, which is expected to close during the fourth quarter of 2015, is subject to shareholder approval as well as certain other customary closing conditions.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing